摘要【目的】 探讨康柏西普联合玻璃体切除术(PPV)治疗增殖期糖尿病性视网膜病变(PDR)的临床疗效。【方法】 选取2020年8月至2022年10月在本院就诊的46例(50眼)PDR患者作为研究对象, 按照随机数字表法分为观察组和对照组,每组23例(25眼)。对照组患者给予单纯23 G PPV治疗, 观察组患者给予康柏西普联合23 G PPV治疗。比较两组患者手术时间及术中和术后情况。【结果】 观察组手术时间显著短于对照组(t=2.47,P<0.05);观察组术后最佳矫正视力(BCVA)度数高于对照组(P<0.05);因医源性视网膜裂孔、视网膜脱落实行的硅油填充率低于对照组(P<0.05)。【结论】 康柏西普联合23 G PPV治疗PDR患者,可有效缩短手术时间,改善患者术后视力, 降低并发症发生率。
Abstract：【Objective】 To investigate the clinical effect of conbercept combined with vitrectomy (PPV) in the treatment of proliferative diabetic retinopathy (PDR). 【Methods】 Totally 46 patients (50 eyes) with PDR, who visited our hospital from August 2020 to October 2022, were selected as the study subjects, and they were randomly divided into two groups. There were 23 patients (25 eyes) in the conventional group who were treated with 23 G PPV alone and 23 patients (25 eyes) in the study group who were treated with conbercept-assisted 23 G PPV. Postoperative follow-up included a comparison of surgical duration and changes in intraoperative and postoperative conditions between the two groups. 【Results】 The average surgical duration in the study group was significantly lower than that in the conventional group (t=2.47, P<0.05). Postoperatively, the best corrected visual acuity (BCVA) in the study group was higher than that in the conventional group. Additionally, the rates of iatrogenic retinal break and retinal detachment treated with silicone oil tamponade were lower in the study group if compared to the conventional group (P<0.05). 【Conclusion】 PDR patients treated with conbercept-assisted 23 G PPV can effectively reduce surgical duration, enhance postoperative visual acuity, and decrease the incidence of complications.
王会艳, 胡鹏, 蒋丽娟, 黄英. 康柏西普联合玻璃体切除术治疗增殖期糖尿病性视网膜病变的临床疗效*[J]. 医学临床研究, 2024, 41(1): 11-13.
WANG Huiyan, HU Peng, JIANG Lijuan, et al. Clinical Effects of Conbercept in Combination with Vitrectomy for Proliferative Diabetic Retinopathy. JOURNAL OF CLINICAL RESEARCH, 2024, 41(1): 11-13.
2024, Vol. 41 
